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Abstract
Background: Mental illness is a substantial and rising contributor to the global burden of disease. Access to and
utilization of mental health care, however, is limited by structural barriers such as specialist availability, time, out-of-
pocket costs, and attitudinal barriers including stigma. Innovative solutions like virtual care are rapidly entering the
health care domain. The advancement and adoption of virtual care for mental health, however, often occurs in the
absence of rigorous evaluation and adequate planning for sustainability and spread.
Methods: A pragmatic randomized controlled trial with a nested comparative effectiveness arm, and concurrent
realist process evaluation to examine acceptability, effectiveness, and cost-effectiveness of the Big White Wall (BWW)
online platform for mental health self-management and peer support among individuals aged 16 and older who
are accessing mental health services in Ontario, Canada. Participants will be randomized to 3 months of BWW or
treatment as usual. At the end of the 3 months, participants in the intervention group will have the opportunity to
opt-in to an intervention extension arm. Those who opt-in will be randomized to receive an additional 3 months of
BWW or no additional intervention. The primary outcome is recovery at 3 months as measured by the Recovery
Assessment Scale-revised (RAS-r). Secondary outcomes include symptoms of depression and anxiety measured with
the Personal Health Questionnaire-9 item (PHQ-9) and the Generalized Anxiety Disorder Questionnaire-7 item
(GAD-7) respectively, quality of life measured with the EQ-5D-5L, and community integration assessed with the
Community Integration Questionnaire. Cost-effectiveness evaluations will account for the cost of the intervention
and direct health care costs. Qualitative interviews with participants and stakeholders will be conducted
throughout.
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Discussion: Understanding the impact of virtual strategies, such as BWW, on patient outcomes and experience, and
health system costs is essential for informing whether and how health system decision-makers can support these
strategies system-wide. This requires clear evidence of effectiveness and an understanding of how the intervention
works, for whom, and under what circumstances. This study will produce such effectiveness data for BWW, while
simultaneously exploring the characteristics and experiences of users for whom this and similar online interventions
could be helpful.
Trial registration: Clinicaltrials.gov NCT02896894. Registered on 31 August 2016 (retrospectively registered).
Keywords: Web-based, Internet, Virtual care, Implementation, Self-management, Recovery
Background
Mental illness is a substantial and rising contributor to the
global burden of disease [1]. In Canada, 1 in 5 people are
affected by this leading cause of disability, associated with
more than $51 billion CAD in annual costs [2]. Utilization
of mental health care, however, is limited by structural
barriers such as specialist availability, geography, time, out-
of-pocket costs for patients [3, 4], and attitudinal barriers
including stigma [4]. It is estimated that under-recognition
and/or stigma act as obstacles to accessing care for at least
50 % of those affected [4–6].
Innovative solutions such as virtual care, broadly
defined as any remote interaction between patients and/
or health care providers using any form of information
technology to enhance healthcare [7, 8], are rapidly
entering the health care domain. While these innovative
solutions may address some mental health care access
issues through components such as anonymity and rapid
availability, their advancement and adoption often
occurs in the absence of rigorous evaluation and
adequate planning for sustainability and spread [9].
Studies evaluating virtual mental health applications
have demonstrated conflicting findings, with some trials
demonstrating no benefits [10] and others demonstrating
substantial improvement among participants [11]. These
conflicting findings illustrate the importance of studying
the processes of implementation, including contextual
factors, and the mechanisms of action that help to deter-
mine whether and how virtual mental health applications
have effects on patient outcomes [12]. Although a wide
variety of theories and methods are available to focus
attention on key issues in the adoption and scale-up of
new technologies, these are only recently being applied in
large implementation studies [13, 14].
In the province of Ontario, Canada, the Ontario Tele-
medicine Network (OTN), a non-profit and government-
funded organization, is the largest provider of telemedicine
services [15]. In 2015, OTN conducted a selection process
to initiate a series of pilot telehomecare interventions for
patients with chronic conditions, ultimately choosing to test
Big White Wall (BWW) for those struggling with mental
health. This manuscript describes the approach to the
evaluation of this virtual mental health application within
the local health care system in Ontario, Canada.
Virtual care application: Big white wall
BWW is an internet-based application, built on evidence-
based components of mental health care (eg. peer support
[16], cognitive behavioural therapy [17]) combined in a
virtual environment that provides anonymity (see
www.bigwhitewall.com). BWW offers users access to self-
assessment tools, a social network that connects people
who have similar problems, and access to on-line courses.
The service is monitored at all times by “Wall Guides”,
trained mental health professionals (psychiatrists, social
workers, and psychologists), ensuring that users are
responded to and that the content posted is appropriate
and safe. BWW was first developed and implemented
within the National Health Service in the UK in 2007, and
is now available in the UK, New Zealand, and the USA
with over 35,000 users since its inception [18]. An
independent pre-post evaluation of BWW users in the UK
over 3 months found that 50 % showed a meaningful
reduction in symptoms using validated scales of depres-
sion and anxiety [18]. While more rigorous evaluations of
BWW are currently underway, it has not yet been
comprehensively evaluated, and not within a Canadian
context.
This protocol outlines a mixed methods study guided
by a theoretical approach to examine the implementa-
tion of BWW in Ontario. The overall approach taken in
this study employs a novel model of integrated know-
ledge translation [19], whereby the health system deci-
sion makers, implementation leads, and scientific
evaluators have been engaged in the development of the
research project from the outset. This approach facili-
tates the assessment of implementation and scalability,
and increases the likelihood that results will have a fu-
ture impact on health system policy.
Methods/design
Study aims
This study aims to evaluate whether the intervention,
BWW, is acceptable, effective and cost-effective. In
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addition, the study aims to generate knowledge on the
implementation processes and outcomes that will inform
future health system decision-making regarding the po-
tential scale-up of this and other mental health virtual
care applications in Ontario.
Hypotheses
We hypothesize that access to BWW will increase men-
tal health recovery orientation and reduce symptoms of
depression and anxiety among patients seeking special-
ized mental health care. Further, we expect that a greater
response to BWW will be predicted by higher baseline
belief in credibility and outcome expectancy of the inter-
vention as well as actual level of engagement with the
intervention. The core mechanisms by which we
hypothesize BWW to be effective include: 1) enhanced
self-efficacy to self-manage mental health conditions
through acquisition of knowledge, personal use of track-
ing tools, and vicarious learning; and 2) rapid access to
peer and facilitated support within a constrained health
care system leading to a feeling of security and enhanced
ability to cope in crisis situations.
Study setting
This study is based in Ontario, Canada’s most populous
province. In Ontario, all physician and hospital mental
health care, including outpatient services located in hos-
pitals, are publicly funded under the single-payer provin-
cial health insurance plan [20]. Subsidized community
services offer some services for free or at a low cost. [20]
There is also a large network of private inter-
professional health providers including social workers,
psychologists and registered psychotherapists who pro-
vide counselling and psychotherapy for a fee [21]. Third
party insurers may offer partial or limited coverage for
these services [22]. Due to limited publicly funded ser-
vices and high costs for private services, public programs
have long wait times on the order of months to a year or
more, and often provide time-limited treatment only
[23, 24]. Although the potential for virtual mental health
care platforms within this resource constrained system is
apparent, few widely accessible platforms exist, and none
with sufficient evidence to warrant their wide scale
adoption into clinical practice.
Within Ontario, three test sites were selected from cit-
ies with populations of approximately 80,000, 150,000,
and 2.5 million. These sites include: 1) a community
general hospital with inpatient and outpatient mental
health services and an emergency department (ED) that
sees a high volume of mental health-related visits, 2) a
psychiatric hospital with inpatient and outpatient mental
health services, and 3) an academic ambulatory care
hospital with a large outpatient mental health program.
With the exception of the ED, the majority of the clinical
programs accept referrals from the community or from
within their respective hospital for assessment and man-
agement of chronic and/or treatment refractory mental
health problems. The third site offers self-referral to
some of the treatment programs with the requirement
that individuals undergo an extensive intake assessment
prior to being formally accepted to the waitlist.
Participant eligibility
Eligible patients are individuals 16 years of age and older
who are seeking mental health care at any of the partici-
pating sites. Inclusion criteria: 1) able to provide in-
formed consent; 2) able to read in English; 3) able and
willing to access the internet, 4) able to navigate an on-
line program independently or with minimal assistance;
and 5) have or are willing to obtain and use an email ad-
dress. Exclusion criteria: There are no exclusion criteria
but clinicians are reminded that BWW is a peer commu-
nity and participants need to be able to coherently and
respectfully interact with others. As such, we do not rec-
ommend individuals with severe psychosis or behav-
ioural disorders be recruited.
Evaluation framework
The RE-AIM framework [25] will guide the study of
whether and how to scale BWW across Ontario. RE-AIM
draws researchers’ attention to the issues of Reach, Effect-
iveness, Adoption, Implementation, and Maintenance (see
Fig. 1). Within this framework, the RCT aims to evaluate
reach and effectiveness, and Realist Evaluation will explore
adoption, implementation and maintenance. Realist
Evaluation [26] is growing in international popularity in
the health services and policy research community [27],
and is proposed for the evaluation of complex health care
interventions [26]. Realist Evaluation has a number of
appealing features for researchers and health system
decision makers, as it does not simply provide a binary in-
dication of whether an intervention works or not. Instead,
it answers the question, “what works, for whom, under
what circumstances” [28]?
Fig. 1 The RE-AIM Framework
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Study design
This study consists of a pragmatic randomized controlled
trial (RCT) with a nested comparative effectiveness arm to
assess the value of intervention extension, with concurrent
Realist Evaluation. At enrollment, participants will be ran-
domized to either immediately receive the intervention,
BWW (immediate treatment group; ITG) or receive access
to BWW after a 3 month waiting period (delayed treat-
ment group; DTG). The DTG will serve as the control
group during the first 3 months. After 3 months of inter-
vention, ITG participants will have the opportunity to opt-
in to an intervention extension arm. Those who opt-in will
be randomized to receive an additional 3 months of BWW
or no additional intervention. A purposefully sampled
sub-group of trial participants, health care providers, and
health system decision makers will be invited to participate
in qualitative interviews throughout. The RCT study flow
is depicted in Fig. 2.
Part 1. Pragmatic randomized controlled trial
Recruitment
Participants will be recruited at a number of entry or
exit points including outpatient clinics and their wait-
lists, emergency department (ED) discharges, and rapid
assessment clinic discharges. Outpatient clinics include
youth mental health services (age 16 and over only),
Fig. 2 Detailed study flow for the RCT. ED: Emergency Department; RA: research assistant; RC: research co-ordinator; BWW: Big White Wall
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adult general psychiatry consultation services (typically
serving mood and anxiety disorders), psychotherapy
services, post-traumatic stress and trauma therapy
services, an outpatient substance use program, and a
borderline personality disorder clinic. These recruitment
settings were selected because: 1) they serve patients
with the potential to benefit from the intervention, 2)
they were identified by the participating sites and OTN
as high priority settings, and 3) they have high volumes
of use and turnover that will allow the implementation
organization to reach their recruitment target. With the
exception of the ED and rapid assessment clinics, the
wait times to access these services vary from 4 months
up to 2 years. Participation in the study will not affect
wait list position or access to services.
Potential participants will be approached by a member
of the clinical staff either by telephone, or in person in the
clinic or ED. Hard-copy pamphlets or a website link to the
study information will be provided. Once a potential par-
ticipant indicates their interest, a research assistant (RA)
or research co-ordinator (RC) will either meet them in
person or contact via telephone to provide more informa-
tion and obtain consent. Consent will include: 1) Consent
to participate in the RCT (required), 2) Consent to be
contacted for a qualitative interview (optional), 3) Consent
to provide individual provincial health insurance plan
(OHIP) number for linkage of survey data to health ad-
ministrative data (optional), and 4) Consent for primary
care provider to be notified of study enrollment (optional).
Separate consent to be re-randomized at 3 months will
be obtained from ITG participants who opt-in to the
nested intervention extension arm of the trial. This will
be done with a question posed at the end of the 3 month
data collection survey.
Allocation and blinding
At enrollment, a 2:1 allocation ratio will be used to
randomize participants to ITG or DTG. This allocation
ratio was chosen to immediately provide the interven-
tion to more participants and increase likelihood of par-
ticipation. Participants and providers will not be blind to
treatment group. Randomization sequences will be gen-
erated independently and will be stratified by site and re-
cruitment setting. Allocation sequence will be concealed
until after baseline data has been collected to blind those
involved in recruiting and consenting procedures. Group
allocation will be revealed by phone or email. At t =
3 months, ITG participants who opt in to the nested
study arm, will be randomized 1:1 to a 3 month BWW
extension (ITG-e) or no extension (ITG-n). Group
allocation will again be revealed via phone or email. The
nested treatment extension arm will be concealed from
participants at enrollment to encourage maximal usage
of the intervention during the first 3 months. All data
analyses will be blinded.
Interventions
Treatment as usual (months 0–3 for DTG) Partici-
pants in the DTG will receive treatment as usual with
no intervention from the study for the first 3 months.
Treatment as usual may include formal or informal
mental health care including pharmacological and non-
pharmacological treatments. Participants recruited at
discharge from clinics or the ED will receive usual
recommendations regarding other services and programs
that would routinely be offered upon discharge from
those settings.
Treatment as usual + BWW (months 0–3 for ITG,
months 4–6 for DTG and ITG-e) Participants will
receive a 3-month subscription to BWW, free of charge.
Use of BWW is participant-driven, with the ability to
utilize the services at any frequency. A unique BWW
access code will be emailed to participants. If registra-
tion has not occurred within 3 days of receipt, a follow-
up call will be made to remind the participant to log in.
For the DTG participants, a study team member will
contact them 3 months after enrollment to remind them
that their access to BWW will start and the access code
will be emailed. Participants randomized to ITG-e will
be able to reactivate their same account once allocation
has been revealed.
Participant safety on BWW All participants maintain
anonymity on the site through a unique non-identifiable
user ID. Study participants will have a unique landing
page that includes contact information for local crisis
services in the event urgent assistance is required. BWW
uses automated word recognition software that will alert
the Wall Guides when potential safety issues are arising
(eg. a user mentions ‘suicide’). The Wall Guides will then
monitor that user’s activity and if deemed clinically
necessary, will intervene to offer support. In the event
that urgent support is required, they will direct them to
use the crisis services listed on the landing page.
Data collection
All baseline and follow-up data will be entered into a
REDCap™ database developed for the RCT. REDCap™ is
confidential and is only accessible to the study personnel
by secure login.
Baseline data At time of consent, participants will
complete a baseline questionnaire assessing socio-
demographics, mental health history, measures of treat-
ment credibility and outcome expectancy, and all outcome
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measures. Due to the length of time required to complete
consent and all baseline questionnaires, baseline data may
be collected in 1 of 3 ways depending on recruitment
setting and participant preference: 1) by web survey
(default); 2) by phone; or 3) in-person hard-copy.
Socio-demographics Baseline data will include partici-
pant age, gender, ethnicity, education, relationship status,
household income, employment status, and living situation.
Mental health history At baseline, we will collect age at
first onset of mental health problems, age at which for-
mal mental health support was first sought, and duration
of current episode.
Baseline belief in treatment credibility and outcome
expectancy Participants are asked to rate their belief in
the credibility of self-help resources to improve mental
health with the author-generated statement: “Self-help
tools including on-line services or books are helpful for
people with mental health problems” on a 4-point scale
from ‘definitely agree’ to ‘completely disagree.’ In
addition, they will be asked about their outcome expect-
ancy of BWW to improve their mental health. Item #4
from the Credibility and Expectancy Questionnaire [29]
will be used, “After having access to BWW for 3 months,
how much improvement in your mental health do you
think will occur?” Participants are asked to rate their
response from 0 to 100 % with options available in 10 %
increments. This single item has been shown to correlate
strongly with psychotherapy outcomes [30].
Follow-up data (3 and 6 Months) REDCap™ will be
automated to push web-based surveys containing all
outcome measures to participant emails 2 weeks prior to
each pre-determined data collection time point. If, after
2 weeks, the participant has not completed the survey, a
follow-up phone call will be made and confirmation of
intention to complete it will be obtained and the link
pushed again, or the questionnaire will be completed
over the phone. For the former option, after 1 week, if
still not complete a second follow-up phone call will be
made and every effort to collect data over the phone will
be made. All outcome measures must be completed
within ±2 weeks of the intended time point.
BWW utilization data BWW will provide a report of
each participants’ use at 2 time points during the study:
1) after all participants have been enrolled for 3 months,
and 2) study end. This will include total number of
logins, average and total time on the site, along with logs
of activity such as pages viewed and posts made.
BWW satisfaction At the end of the BWW access
period (month 3 for ITG, month 6 for DTG) partici-
pants will be asked to rate BWW overall and indicate if
they would recommend it, pay for it, and continue to
use it if available.
Outcome measures
Primary and secondary outcomes The primary
outcome is the total score on the Recovery Assessment
Scale-revised (RAS-r) at 3 months. The RAS-r is a
24-item validated pan-diagnostic consumer-oriented
outcome measure [31]. All items are scored on a 5-point
scale from ‘strongly disagree’ to ‘strongly agree.’ The
choice of the RAS-r reflects the current “recovery era”
for mental health policy and services and the increasing
focus on consumer achievement of satisfying and fulfill-
ing lives, rather than being symptom free [31]. Second-
ary outcomes include the five subscale scores of the
RAS-r: 1) personal confidence and hope, 2) willingness
to ask for help, 3) goal and success orientation, 4) reli-
ance on others, and 5) not dominated by symptoms;
symptoms of depression and anxiety measured with the
Personal Health Questionnaire-9 item (PHQ-9) and the
Generalized Anxiety Disorder Questionnaire-7 item
(GAD-7) respectively; quality of life measured with the
EuroQOL group’s EQ-5D-5 L [32]; and community
integration assessed with the Community Integration
Questionnaire (CIQ) [33]. The 15-item CIQ is a brief,
reliable measure of a person’s level of integration into
the home and community. The overall score ranges from
0 to 29 with a higher score indicating better integration.
The CIQ can also be divided into 3 subscales: 1) home
integration, 2) social integration, and 3) productivity
[33]. Timing of the completion of outcome assessments
is outlined in Table 1.
Health care utilization and costs Self-reported health
care utilization will be assessed with the Client Service
Receipt Inventory [34], adapted for the Ontario context.
This measure captures utilization of physician and
hospital services as well as community mental health
services. Health administrative data will be used to
validate reports of physician and hospital care, however,
community service use and non-physician visits are not
captured in Ontario data. Studies of reliability of self-
report data over a 3 month recall period demonstrate
approximately 60 % exact match with roughly equal
proportions of over and under-reporting [35]. High emo-
tional distress may be associated with over-reporting,
and hospital and ED use is typically more accurately
self-reported than outpatient care [35]. The CSRI will
also assess prescribed medication and adherence. Self-
reported out-of-pocket costs for medication, laboratory
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investigations, mental health services, and physical
health services will be captured using validated questions
from the Commonwealth Fund Survey of patients with
Complex Needs [36].
Health administrative data will be retrieved after study
completion from the Institute for Clinical Evaluative
Sciences (ICES), a not-for-profit research institute
encompassing a secure and accessible array of Ontario's
health-related data. At ICES, individual-level health care
and socio-demographic data from various sources are
de-coded and linked using an encrypted health care
number (ICES Key Number). We will extract individual
data on inpatient, ED, outpatient health care utilization,
as well as prescription drug costs (for people on social
assistance or over age 65) during the study period and
link to individual survey data using encrypted OHIP
identifiers created by ICES authorized personnel.
Individual health care costs will be determined using
methods developed for use with Ontario data [37].
We will track incremental costs associated with BWW
using unit prices from expenditures related to its use
(capital and operating costs such as license fees) as
well as human resources required to support its
implementation.
Adverse events
There is a growing consensus that adverse events (AEs)
need to be evaluated in behavioural intervention trials
[38, 39], as there is a theoretical risk of deterioration,
especially if online self-help tools are misunderstood or
not properly applied [38]. We will compare pre-defined
AEs (see Table 2) between the ITG and DTG participants
at 3 months, and the ITG-e and ITG-n participants at
6 months for clinically important differences that may be
a result of BWW. Moreover, an independent data safety
and monitoring board (DSMB) comprised of three
content and methodology experts assembled for this trial
will review available AE data at two interim time points:
after the first 150 participants have completed 3 months,
and again after 500 participants have completed 3 months,
to determine if any investigation is required and if the trial
is safe to continue. Health administrative data will not be
available within this timeframe and will not be reviewed
by the DSMB. DSMB terms of reference are available from
the study investigators.
Data analysis
In order to meet stakeholder deliverables, analyses will
be completed at 2 time points: 1) analysis of 3 month
Table 1 Timing of outcome assessments
Measures/Assessments Baseline 3 months 6 months
RAS-r X X X
PHQ-9 X X X
GAD-7 X X X
CIQ X X X
EQ-5D-5 L X X X
Adapted CSRIa X X X
Out-of-pocket costsb X X X
Health Administrative Data N/A X X
BWW satisfaction N/A X (ITG) X (DTG)
RAS-r recovery assessment scale-revised, PHQ-9 personal health questionnaire,
9-item, GAD-7 generalized anxiety disorder questionnaire, 7-item, CIQ community
integration questionnaire, EQ-5D-5 L Euro-QOL quality of life measure, CSRI client
service receipt inventory, BWW big white wall, ITG immediate treatment group,
DTG delayed treatment group, N/A not assessed
aAdapted for the Ontario health care context
bIncludes costs for medication, laboratory investigations, mental health
services, and physical health services
Table 2 Adverse Events
Adverse Event Measure Description
Mental health Hospitalization CSRI; Health
administrative data
Number of hospitalizations on a psychiatric unit
Mental health ED visit CSRI; Health
administrative data
Number of ED visits for a mental health reason
Crisis service use CSRI Number of times using crisis supports
Increased suicidal ideation PHQ-9 item 9 Increase in PHQ-9 item 9 score
Death Health administrative data All-cause mortality
Worsening depression or anxiety PHQ-9, GAD-7 Increase in PHQ-9 or GAD-7 score
over the prior 3 months
Declining social and
community integration
CIQ Decrease in CIQ score over the prior 3 months
Worsening disability EQ-5D-5 L Decrease in EQ-5D-5L scores over the prior 3 months
Medication discontinuation Author question
added to CSRI
Self-reported discontinuation of psychotropic
medication without provider knowledge
CSRI client service receipt inventory, PHQ-9 personal health questionnaire, 9-item, GAD-7 generalized anxiety disorder questionanire, 7-item, CIQ community
integration questionnaire, EQ-5D-5 L Euro-QOL quality of life measure
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data once all 3 month data have been collected, and 2)
analysis of 6 month data at study end. Health care ad-
ministrative data will only be analyzed after study end.
Primary and secondary analyses Baseline descriptive
statistics will be generated overall, between treatment
groups and between recruitment settings. Employment
status and medication use will be described at baseline
and 3 months. Prior 3-month health care utilization
assessed with the CSRI (and validated with health
administrative data when available) will be described at
baseline and at 3 months. All primary and secondary
outcomes will be described at baseline and 3 months,
including the RAS-r and CIQ subscales. In addition, at
baseline and 3 months, we will describe the proportion
of participants with PHQ-9 and GAD-7 scores of 10 or
more, indicative of clinically important levels of depres-
sion and anxiety [40], respectively. At 3 months, we will
describe clinically important cutoffs on the PHQ-9 and
GAD-7 including a reduction of 5 or more points from
baseline (clinically meaningful change), reduction in
score of 50 % or more from baseline (response), and a
score less than 10 (remission) [40]. Adverse event de-
scriptive data will be reported at 3 months, and again at
6 months for the BWW extension group. BWW satisfac-
tion descriptive data will be reported at 3 months for
ITG participants and 6 months for DTG participants.
The primary outcome, RAS-r at 3 months, will be ana-
lyzed with an intent-to-treat analysis using an ANCOVA
controlling for baseline RAS-r score as well as treatment
group, unadjusted and adjusted for baseline PHQ-9,
baseline GAD-7, age, sex, education, relationship status,
household income, duration of episode, and recruitment
setting. In sensitivity analysis, we will repeat this using a
marginal structural model to account for attrition.
The same analysis will be repeated for all secondary
outcomes at 3 months controlling for baseline score and
treatment group. Analysis of 3 month data will be
completed after all 3 month data have been collected.
In the subset of ITG participants who opt in to the nested
extension study, we will examine outcomes at 6 months
between treatment groups. Analysis of primary and second-
ary outcomes will be repeated as described above, control-
ling for scores at both baseline and 3 months.
Exploratory analyses The first exploratory analysis will
examine a subset of the ITG group who had a PHQ-9 or
GAD-7 score of at least 10 at baseline. Participants will be
categorized as ‘responders’ or ‘non-responders’ based on
whether or not they achieved at least a 50 % reduction in
the PHQ-9 or GAD-7 at 3 months relative to baseline. A
logistic regression model will be built to predict whether
or not they were a responder using age, gender, education,
relationship status, household income, baseline belief in
treatment credibility and outcome expectancy, and re-
cruitment setting as predictors. We will also assess the
contribution of BWW utilization, outpatient mental
health visits, and medication changes during the interven-
tion months as predictors of response.
Second, we will examine engagement with the BWW
among ITG participants. The number of logins and total
time on the site will be separately predicted with age,
gender, education, relationship status, living situation,
household income, baseline belief in treatment credibil-
ity and outcome expectancy, baseline PHQ-9 and GAD-
7 scores, duration of current episode, recruitment setting
and outpatient mental health visits.
Economic evaluation The combination of program
costs, out-of-pocket costs and costs in the health care
system will be used to determine the total costs
associated with participants in the program. Incre-
mental cost-effectiveness will be assessed using an
incremental cost-effectiveness ratio calculated as the
difference in costs between DTG and ITG divided by
the difference in outcomes between these groups.
Confidence intervals around these estimates will be
calculated using nonparametric bootstrapping resampling
techniques (with 10,000 replications).
Power calculation We have performed a power calcula-
tion assuming a sample size of 1000 participants which
is the minimum target recruitment desired by the
funder. Using data from other recent studies of internet
based mental health interventions [10], we have
calculated power assuming a conservative 30 % attrition
rate. The minimal detectable difference between the two
treatment groups was calculated assuming an ANCOVA
analysis with a 0.8 correlation between baseline and
3-month follow-up RAS-r measurements. With a sample
size of 700 accounting for attrition, allocated in a 2:1
ratio, using an alpha of 0.05 and power of 0.9, we are
able to detect a difference of 1.35 on the RAS-r.
Part 2. Qualitative process evaluation
Recruitment
Study participants. The qualitative research team will
purposefully sample from the pool of interested ITG
participants who consented to be contacted for an inter-
view at study enrollment. We aim to interview 4-6
participants at each site, spanning different age categor-
ies, for a total of 12–15 patient participants.
Health care stakeholders Qualitative interviews will be
completed with 5–7 health care providers at each site;
2–4 organizational leaders at each site (for example,
clinical managers); and 5–7 health system decision
makers in Ontario. These participants will be identified
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by clinical site leads using a snowball sampling process
to identify key informants.
Data collection
Qualitative interviews were developed with specific
reference to Realist Evaluation methodology [26–28],
incorporating a focus on the contexts, mechanisms, and
outcomes of BWW implementation. Guided by the
RE-AIM framework [25], the interviews will focus on
different content for each participant group. Interviews
with participants will focus on how the patient manages
his or her mental health in the community, perspectives
of BWW, and how BWW is used in daily life. If the par-
ticipant has not engaged with BWW as evidenced by no
or very few times logged in, the qualitative interview
will include questions about why not, and what alter-
native strategies the patient uses to manage mental
health in the community. Participants will be offered
the opportunity to conduct the interviews remotely
using personal computer videoconferencing with the
option to enable screen sharing of the participant’s
computer. Alternatively, a telephone interview will be
arranged. Separate informed consent will be obtained
for all qualitative interviews which will be audio-
recorded.
Participants who opt in for the intervention extension
arm of the study will again be asked whether they are
interested in participating in a qualitative interview.
Participants who identify as willing to be contacted may
or may not have participated in a qualitative interview in
the first phase of the study, and will be purposefully
sampled and interviewed 2–4 weeks after the re-
randomization process in the same manner as the initial
interviews. We will again recruit 2–3 participants at
each of the three sites for a total of 12–15 patient partic-
ipants from the extension arm.
Qualitative interviews with health care provider par-
ticipants will include questions regarding perspectives
on mental health services in Ontario, and the value of
virtual care interventions such as BWW for promoting
self-management of mental health. Interviews with
organizational leaders and health systems decision-makers
will include questions about the context of mental health
services in Ontario, the effectiveness of virtual care inter-
ventions to promote mental health self-management in
the community, and the procurement and implementation
of virtual care interventions such as BWW.
In addition to qualitative interviews, we will conduct
qualitative observations of the BWW educational
sessions delivered to health care providers by the imple-
mentation team from OTN. The researcher will take
detailed notes regarding the content of the education
session, including a specific focus on how health care
providers react to the intervention, what questions they
ask, and how the education session emphasizes imple-
mentation. These sessions will not be audio-recorded,
rather observations will be guided by a structured obser-
vation worksheet.
Data analysis
Qualitative interviews and written observations will be
transcribed into word documents and prepared for quali-
tative analysis. Both observational data and interview data
will be analyzed using thematic analysis strategies [28, 41],
identifying key themes that demonstrate important
contextual influences and practices related to the imple-
mentation and evaluation of the virtual care application
within the actual contexts of health care delivery. At least
two researchers will review the transcripts, field and
analytical notes independently and meet to develop a code
workbook with emergent key themes. If a discrepancy
emerges between the two researchers, a third researcher
will review and consensus will be achieved. The findings
of the qualitative data in conjunction with the quantitative
outcomes data will be used to develop statements of the
relationships between (a) key contextual factors, (b) the
mechanisms by which they effect the implementation/up-
take of BWW, and (c) the impact on the outcomes of
BWW itself (in Realist Evaluation these statements are
referred to as “Context-Mechanism-Outcome Configura-
tions”) [28]. These statements will be used to develop
understanding of (a) the specific mechanisms by which
BWW is effective for users, and (b) strategies to inform
the future implementation of BWW and/or similar
interventions on a larger scale.
Limitations
The requirements of health system stakeholders involved
in this initiative necessitated a number of compromises in
the design of this evaluation. First, the sample size
requested by the funder necessitated broad inclusion
criteria which is pragmatic but may present challenges
around interpreting efficacy, particularly if no effect of the
intervention is observed. We have limited recruitment to
treatment settings where BWW is theorized to have the
greatest applicability, and will seek to understand through
our analysis and qualitative data if particular participant
groups respond differently. Second, stakeholder desire for
all participants to receive the intervention within a specific
time interval meant that a control arm could not be con-
tinued throughout, and necessitated a short follow-up
period, which will limit the interpretation of sustained
intervention effectiveness. We have included a nested
intervention extension arm open to interested participants
to pragmatically evaluate the effectiveness of the sustained
intervention in a self-selected patient group. Third, the
specific intervention, BWW, was selected by the partners
and although the process evaluation will seek to determine
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which components and mechanisms lead to the observed
effects, it is uncertain how the findings of the study will be
generalizable to other on-line mental health interventions.
Discussion
Mental health recovery through self-management and life
fulfillment is a priority across countries around the world
in this recovery-oriented era [31]. Virtual strategies are a
promising solution. Understanding the impact of these
virtual strategies, such as BWW, on patient outcomes,
patient experience, and health system costs is essential for
informing whether and how health system decision-
makers can support these strategies system-wide [42].
This requires clear evidence of effectiveness and an under-
standing of how the intervention works, for whom, and
under what circumstances [28]. This study will produce
such effectiveness data for BWW, while simultaneously
exploring the characteristics and experiences of users for
whom this and similar online interventions could be help-
ful, within our unique local context.
Trial status
The trial is actively recruiting at all three sites. The first
participant was recruited July 22, 2016 with a total of
475 participants consented to date.
Abbreviations
AE: Adverse event; ANCOVA: Analysis of covariance; BWW: Big white wall;
BWW: Big white wall; CIQ: Community integration questionnaire; CSRI: Client
service receipt inventory; DSMB: Data safety and monitoring board;
DTG: Delayed treatment group; ED: Emergency Department; EQ-5D-
5 L: EuroQOL five dimensions questionnaire-5 level; GAD-7: Generalized
anxiety disorder questionnaire-7 item; ICES: Institute for clinical evaluative
sciences; ITG: Immediate treatment group; ITG-e: Immediate treatment
group-extension; ITG-n: Immediate treatment group-no extension;
OHIP: Ontario health insurance plan; OTN: Ontario telemedicine network;
PHQ-9: Personal health questionnaire-9 item; RA: Research assistant; RAS-
r: Recovery assessment scale-revised; RC: Research co-ordinator;
RCT: Randomized controlled trial
Acknowledgements
The authors would like to acknowledge Ed Brown, Rhonda Wilson, Harriet
Ekperigin and Nelisha Andrews from the Ontario Telemedicine Network for
their engagement and operational oversight.
Funding
This study is sponsored by the Ontario Telemedicine Network and received
funding through a competitive research contract awarded by Canada Health
Infoway and the Ontario Ministry of Health and Long Term Care which are
both government agencies. No commercial funding was obtained for this
study.
Availability of data and materials
Not applicable.
Authors’ contributions
JMH, JS, LJ, NMI, LD, TJ, and RSB were responsible for the study design. JMH
and JS prepared the first draft of the protocol. AC provided statistical
expertise and created the analysis plan. PA, WW, JT, DL, AM, PC, GM, MM, RY,
IW and NO all offered methodological expertise into the health system
context for the study, study procedures, outcomes, analysis, and contributed
to revision of the protocol. All authors approved the final version of this
manuscript for submission.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
All participants will provide informed consent to participate in this study. This
protocol received research ethics approval from the following Research Ethics
Boards: Women’s College Hospital (2016-0019-E), Ontario Shores (16-005B_SB),
Lakeridge Health (2016-008), St. Michael’s Hospital (16-239).
Author details
1Women’s College Hospital Institute for Health Systems Solutions and Virtual
Care, Women’s College Hospital, 76 Grenville St, Toronto, ON, Canada.
2Department of Psychiatry, Women’s College Hospital and University of
Toronto, 76 Grenville St, Toronto, ON, Canada. 3Women’s College Research
Institute, Women’s College Hospital, 76 Grenville St, Toronto, ON, Canada. 4Li
Ka Shing Knowledge Institute, St. Michael’s Hospital, 209 Victoria St, Toronto,
ON, Canada. 5Department of Family and Community Medicine, Women’s
College Hospital and University of Toronto, 76 Grenville St, Toronto, ON,
Canada. 6Institute for Health Policy, Management and Evaluation, University
of Toronto, 155 College St, Toronto, ON, Canada. 7Institute for Clinical
Evaluative Sciences, 2075 Bayview Ave, Toronto, ON, Canada. 8Department of
Family and Community Medicine, University of Toronto, 500 University Ave,
Toronto, ON, Canada. 9Women’s College Hospital Family Health Centre, 77
Grenville St, Toronto, ON, Canada. 10OntarioMD, 150 Bloor St, Toronto, ON,
Canada. 11Rotman School of Management, University of Toronto, 105 St.
George St, Toronto, ON, Canada. 12Division of General Internal Medicine and
Geriatrics, University Health Network and Sinai Health System, and University
of Toronto, 600 University Ave, Toronto, ON, Canada. 13Department of
Medicine, University of Toronto, 1 King’s College Circle #3172, Toronto, ON,
Canada. 14Li Ka Shing Centre for Healthcare Analytics Research and Training,
St. Michael’s Hospital, 209 Victoria St, Toronto, ON, Canada. 15Leslie Dan
Faculty of Pharmacy, University of Toronto, 144 College St, Toronto, ON,
Canada.
Received: 9 September 2016 Accepted: 30 September 2016
References
1. Whiteford HA, Ferrari AJ, Degenhardt L, Feigin V, Vos T. The global burden
of mental, neurological and substance use disorders: an analysis from the
global burden of disease study 2010. PLoS One. 2015;10(2):e0116820.
2. Lim KL, Jacobs P, Ohinmaa A, Schopflocher D, Dewa CS. A new population-
based measure of the economic burden of mental illness in Canada. Chron
Dis Can. 2008;28(3):92–8.
3. Kurdyak P, Stukel TA, Goldbloom D, Kopp A, Zagorski BM, Mulsant BH.
Universal coverage without universal access: a study of psychiatrist supply
and practice patterns in Ontario. Open Med. 2014;8(3):e81–93.
4. Mojtabai R, Olfson M, Sampson NA, Jin R, Druss B, Wang PS, et al. Barriers to
mental health treatment: results from the national comorbidity survey
replication. Psychol Med. 2011;41(8):1751–61.
5. Fleury MJ, Grenier G, Bamvita JM, Perreault M, Kestens Y, Caron J.
Comprehensive determinants of health service utilisation for mental health
reasons in a canadian catchment area. Int J Equity Health. 2012;11:20.
doi:10.1186/1475-9276-11-20.
6. Vasiliadis HM, Lesage A, Adair C, Boyer R. Service use for mental health
reasons: cross-provincial differences in rates, determinants, and equity of
access. Can J Psychiatry. 2005;50(10):614–9.
7. Jamieson T, Wallace R, Armstrong K, Agarwal P, Griffin B, Wong I, et al. Virtual
care: a framework for a patient-centric system. Toronto: Women’s College
Hospital Institute for Health Systems Solutions and Virtual Care; 2015.
8. Naylor D, Girard F, Mintz J, Fraser N, Jenkins T, Power C. In: Health Mo,
editor. Unleashing innovation: excellent healthcare for Canada - report of
the advisory panel on healthcare innovation. 2015. http://www.
healthycanadians.gc.ca/publications/health-system-systeme-sante/report-
healthcare-innovation-rapport-soins/alt/report-healthcare-innovation-
rapport-soins-eng.pdf. Accessed 7 Sept 2016.
Hensel et al. BMC Psychiatry  (2016) 16:350 Page 10 of 11
9. Greenhalgh T, Shaw S, Wherton J, Hughes G, Lynch J, Hinder S, et al. SCALS: a
fourth-generation study of assisted living technologies in their organisational,
social, political and policy context. BMJ Open. 2016;6(2):e010208.
10. Gilbody S, Littlewood E, Hewitt C, Brierley G, Tharmanathan P, Araya R, et al.
Computerised cognitive behaviour therapy (cCBT) as treatment for
depression in primary care (REEACT trial): large scale pragmatic randomised
controlled trial. BMJ. 2015;351:h5627.
11. Beshai S, Wallace LM, Mcdougall KH, Waldmann K, Stea JN. Reduced contact
cognitive-behavioral interventions for adult depression: a review. J Psychol.
2016;150(2):252–279.
12. Moore GF, Audrey S, Barker M, Bond L, Bonell C, Hardeman W, et al. Process
evaluation of complex interventions: medical research council guidance.
BMJ. 2015;350:h1258.
13. Gold R, Hollombe C, Bunce A, Nelson C, Davis JV, Cowburn S, et al.
Study protocol for “study of practices enabling implementation and
adaptation in the safety Net (SPREAD-NET)”: a pragmatic trial comparing
implementation strategies. Implement Sci. 2015;10:144.
doi:10.1186/s13012-015-0333-y.
14. Desveaux L, Gomes T, Tadrous M, Jeffs L, Taljaard M, Rogers J, et al.
Appropriate prescribing in nursing homes demonstration project (APDP)
study protocol: pragmatic, cluster-randomized trial and mixed methods
process evaluation of an Ontario policy-maker initiative to improve
appropriate prescribing of antipsychotics. Implement Sci. 2016;11:45.
doi:10.1186/s13012-016-0410-x.
15. Ontario Telemedicine Network: OTN. 2016. https://otn.ca/. Accessed 8 Sept 2016.
16. Pfeiffer PN, Heisler M, Piette JD, Rogers MA, Valenstein M. Efficacy of peer support
interventions for depression: a meta-analysis. Gen Hosp Psyiatry. 2011;33(1):29–36.
17. Hofmann SG, Asnaani A, Vonk IJ, Sawyer AT, Fang A. The efficacy of cognitive
behavioral therapy: a review of meta-analyses. Cognit Ther Res. 2012;36(5):427–40.
18. Big White Wall. Research and outcomes: BWW outcomes and cost
effectiveness - headlines. 2014. https://www.bigwhitewall.com/info/
research-and-outcomes/#.V4PPUvmU1aQ . Accessed 11 July 2016.
19. Kothari A, Wathen CN. A critical second look at integrated knowledge
translation. Health policy (Amsterdam, Netherlands). 2013;109(2):187–91.
20. Health Canada. Canada’s health care system. 2012. http://www.hc-sc.gc.ca/hcs-
sss/pubs/system-regime/2011-hcs-sss/index-eng.php . Accessed 11 July 2016.
21. Stephens T, Joubert N. The economic burden of mental health problems in
Canada. Chron Dis Inj Can. 2001;22(1):18.
22. Lines E. Out of pocket. Canadian Mental Health Association, Ontario; 2007.
http://ontario.cmha.ca/network/out-of-pocket/ . Accessed 7 Sept 2016.
23. Children’s Mental Health Ontario. 2016 report card: child & youth mental
health. 2016. http://www.kidsmentalhealth.ca/about_us/cmho-report-card-
2016.php. Accessed 13 July 2016.
24. Mental Health Commission of Canada. Toward recovery & well-being: a
framework for a mental health strategy in Canada. 2009. http://www.
mentalhealthcommission.ca/English/document/241/toward-recovery-and-
well-being. Accessed 7 Sept 2016.
25. Glasgow RE, Vogt TM, Boles SM. Evaluating the public health impact of
health promotion interventions: the RE-AIM framework. Am J Public
Health. 1999;89(9):1322–7.
26. Lamont T, Barber N, de Pury J, Fulop N, Garfield-Birkbeck S, Lilford R, et al. New
approaches to evaluating complex health and care systems. BMJ. 2016;352:i154.
27. Marchal B, van Belle S, van Olmen J, Hoerée T, Kegels G. Is realist evaluation
keeping its promise? A review of published empirical studies in the field of
health systems research. Evaluation. 2012;18(2):192–212.
28. Pawson R. The science of evaluation: a realist manifesto. London: Sage
Publications Ltd; 2013.
29. Devilly GJ, Borkovec TD. Psychometric properties of the credibility/
expectancy questionnaire. J Behav Ther Exp Psychiatry. 2000;31(2):73–86.
30. Price M, Anderson P, Henrich CC, Rothbaum BO. Greater expectations:
using hierarchical linear modeling to examine expectancy for treatment
outcome as a predictor of treatment response. Behav Ther.
2008;39(4):398–405.
31. Salzer MS, Brusilovskiy E. Advancing recovery science: reliability and validity
properties of the recovery assessment scale. Psychiatr Serv. 2014;65(4):442–53.
32. Euroqol. Valuation of EQ-5D. http://www.euroqol.org/about-eq-5d/valuation-
of-eq-5d.html. Accessed 7 Sept 2016.
33. Willer B, Ottenbacher KJ, Coad ML. The community integration questionnaire.
A comparative examination. A J Phys Med Rehabil. 1994;73(2):103–11.
34. Knapp M, Beecham J. Costing mental health services. Psychol Med.
1990;20(4):893–908.
35. Bhandari A, Wagner T. Self-reported utilization of health care services:
improving measurement and accuracy. Med Care Res Rev. 2006;63(2):217–35.
36. Schoen C, Osborn R, Squires D, Doty M, Pierson R, Applebaum S. New 2011
survey of patients with complex care needs in eleven countries finds that
care is often poorly coordinated. Health Aff. 2011;30(12):2437–48.
37. Wodchis WP, Bushmeneva K, Nikitovic M, McKillop I. Guidelines on person-
level costing using administrative databases in Ontario. 2013. http://www.
hsprn.ca/uploads/files/Guidelines_on_PersonLevel_Costing_May_2013.pdf.
Accessed 7 Sept 2016.
38. Rozental A, Andersson G, Boettcher J, Ebert DD, Cuijpers P, Knaevelsrud C,
et al. Consensus statement on defining and measuring negative effects of
internet interventions. Internet Interv. 2014;1(1):12–9.
39. Duggan C, Parry G, McMurran M, Davidson K, Dennis J. The recording of
adverse events from psychological treatments in clinical trials: evidence from a
review of NIHR-funded trials. Trials. 2014;15:335. doi:10.1186/1745-6215-15-335.
40. Löwe B, Unützer J, Callahan CM, Perkins AJ, Kroenke K. Monitoring
depression treatment outcomes with the patient health questionnaire-9.
Med Care. 2004;42(12):1194–201.
41. Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol.
2006;3(2):77–101.
42. Buntin MB, Burke MF, Hoaglin MC, Blumenthal D. The benefits of health
information technology: a review of the recent literature shows
predominantly positive results. Health Aff. 2011;30(3):464–71.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Hensel et al. BMC Psychiatry  (2016) 16:350 Page 11 of 11
